CU06-1004

01/01/2020 - "Treatment with CU06-1004 (previously called Sac-1004) ameliorates endothelial dysfunction by inhibiting hyperpermeability and inflammation. "
04/06/2023 - "In this study, we aimed to elucidate the effect of CU06-1004 in terms of prevention of inflammation and endothelial dysfunction in an ALI mouse model. "
01/01/2020 - "In groups of NASH induced mice for both 3 and 6 weeks, CU06-1004 significantly reduced the hepatic expression of genes related to lipogenesis, inflammation, and cell adhesion. "
04/06/2023 - "Efficacy of CU06-1004 via regulation of inflammation and endothelial permeability in LPS-induced acute lung injury."
05/01/2022 - "Obesity is a major cause of chronic inflammation, and the effect of CU06-1004 on obesity has not been studied yet. "

01/01/2021 - "Correction: The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice."
01/01/2020 - "The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice."

01/01/2017 - "Here, we report on the protective effects of Sac-1004 on cerebral ischemia-reperfusion (I/R) injury. "
01/01/2017 - "Using a rat model of transient focal cerebral ischemia, it was shown that Sac-1004 effectively ameliorated neurological deficits and ischemic damage. "
01/01/2020 - "CU06-1004 (endothelial dysfunction blocker) ameliorates astrocyte end-feet swelling by stabilizing endothelial cell junctions in cerebral ischemia/reperfusion injury."
01/01/2017 - "Sac-1004, a vascular leakage blocker, reduces cerebral ischemia-reperfusion injury by suppressing blood-brain barrier disruption and inflammation."

01/01/2023 - "CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome."
05/15/2014 - "Moreover, cancer stem cell population dropped substantially in Sac-1004 treated tumor tissues. "
05/15/2014 - "Sac-1004 could enhance vascular junction integrity in tumor vessels and thereby inhibit vascular leakage and enhance vascular perfusion. "
01/01/2020 - "CU06-1004 combination therapy consistently prolonged the survival of tumor-bearing mice by decreasing tumor growth. "
01/01/2020 - "Herein, we report stabilization of tumor blood vessels by endothelial dysfunctional blocker CU06-1004, which modified the TME and showed synergistic effects with immunotherapy anti-PD-1 antibody. "

01/01/2020 - "CU06-1004 (endothelial dysfunction blocker) ameliorates astrocyte end-feet swelling by stabilizing endothelial cell junctions in cerebral ischemia/reperfusion injury."
02/01/2023 - "Our previous study showed that CU06-1004, an endothelial cell dysfunction blocker, prevented vascular leakage, enhanced vascular integrity in ischemic reperfusion injury, and promoted the normalization of tumor vasculature. "
01/01/2017 - "Sac-1004, a vascular leakage blocker, reduces cerebral ischemia-reperfusion injury by suppressing blood-brain barrier disruption and inflammation."
01/01/2022 - "CU06-1004 enhances vascular integrity and improves cardiac remodeling by suppressing edema and inflammation in myocardial ischemia-reperfusion injury."